CN101797235B - Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof - Google Patents
Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof Download PDFInfo
- Publication number
- CN101797235B CN101797235B CN2010101290751A CN201010129075A CN101797235B CN 101797235 B CN101797235 B CN 101797235B CN 2010101290751 A CN2010101290751 A CN 2010101290751A CN 201010129075 A CN201010129075 A CN 201010129075A CN 101797235 B CN101797235 B CN 101797235B
- Authority
- CN
- China
- Prior art keywords
- sodium
- carbosulfonate
- orally disintegrating
- mesh sieve
- disintegrating tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000011734 sodium Substances 0.000 title claims description 59
- 229910052708 sodium Inorganic materials 0.000 title claims description 59
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims description 58
- 239000006191 orally-disintegrating tablet Substances 0.000 claims abstract description 43
- 239000007884 disintegrant Substances 0.000 claims abstract description 32
- 239000000796 flavoring agent Substances 0.000 claims abstract description 21
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 21
- 239000000945 filler Substances 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000005550 wet granulation Methods 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims description 28
- 229920002472 Starch Polymers 0.000 claims description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 239000008107 starch Substances 0.000 claims description 27
- 235000019698 starch Nutrition 0.000 claims description 27
- 239000003826 tablet Substances 0.000 claims description 27
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 24
- 238000005469 granulation Methods 0.000 claims description 20
- 230000003179 granulation Effects 0.000 claims description 20
- 229960000913 crospovidone Drugs 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 17
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 17
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 16
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 16
- 229940041616 menthol Drugs 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 14
- 229930195725 Mannitol Natural products 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 239000000594 mannitol Substances 0.000 claims description 14
- 235000010355 mannitol Nutrition 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 12
- 108010011485 Aspartame Proteins 0.000 claims description 11
- 239000000605 aspartame Substances 0.000 claims description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 11
- 235000010357 aspartame Nutrition 0.000 claims description 11
- 229960003438 aspartame Drugs 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 229940069328 povidone Drugs 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 28
- 210000000214 mouth Anatomy 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 208000032843 Hemorrhage Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000009747 swallowing Effects 0.000 abstract description 4
- 229960004353 carbazochrome sodium sulfonate Drugs 0.000 abstract description 3
- 239000003651 drinking water Substances 0.000 abstract description 3
- 235000020188 drinking water Nutrition 0.000 abstract description 3
- HLFCZZKCHVSOAP-WXIWBVQFSA-M sodium;(5e)-5-(carbamoylhydrazinylidene)-1-methyl-6-oxo-2,3-dihydroindole-2-sulfonate Chemical compound [Na+].NC(=O)N\N=C/1C(=O)C=C2N(C)C(S([O-])(=O)=O)CC2=C\1 HLFCZZKCHVSOAP-WXIWBVQFSA-M 0.000 abstract description 3
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229940032147 starch Drugs 0.000 description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 229960001855 mannitol Drugs 0.000 description 13
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 8
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910002055 micronized silica Inorganic materials 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
技术领域 technical field
本发明涉及一种药物制剂,特别涉及一种卡络磺钠口腔崩解片,还涉及该口腔崩解片的制备方法。The invention relates to a pharmaceutical preparation, in particular to an orally disintegrating tablet of sodium carbosulfonate, and also relates to a preparation method of the orally disintegrating tablet.
背景技术 Background technique
片剂具有质量稳定、剂量准确、服用和携带方便、生产机械化程度高、生产成本低等优点,是目前最常用的药物剂型之一。但同时因其存在崩解较慢、生物利用度较低、部分患者吞服较困难等不足,在应用上受到一定程度的限制。近年来,口腔崩解片、分散片和舌下片等新型片剂不断涌现。口腔崩解片是一种在口腔内不需水即能快速崩解或溶解的片剂,具有吸收快、起效快、肝脏首过效应小、生物利用度高、胃肠道刺激小、服用方便等优点,特别适合于老人、儿童、卧床、吞咽困难或饮水不便的患者。Tablet has the advantages of stable quality, accurate dosage, convenient taking and carrying, high degree of production mechanization, and low production cost. It is one of the most commonly used pharmaceutical dosage forms at present. But at the same time, due to its slow disintegration, low bioavailability, and difficulty in swallowing for some patients, its application is limited to a certain extent. In recent years, new types of tablets such as orally disintegrating tablets, dispersible tablets and sublingual tablets have emerged. Orally disintegrating tablet is a tablet that can disintegrate or dissolve quickly without water in the oral cavity. Convenient and other advantages, especially suitable for the elderly, children, patients who are bedridden, have difficulty swallowing or have inconvenient drinking water.
卡络磺钠(Carbazochrome Sodium Sulfonate),化学名称为1-甲基-6-氧代-2,3,5,6-四氢吲哚-5-缩氨脲-2-磺酸钠盐三水合物,是日本田边三菱制药株式会社率先研发成功的新一代止血药,具有止血效果好、起效迅速、作用持久、毒副作用小等优点,主要用于泌尿系统、上消化道、呼吸道和妇产科出血疾病,对泌尿系统疗效较为显著,亦可用于手术出血的预防及治疗等。Carbazochrome Sodium Sulfonate, the chemical name is 1-methyl-6-oxo-2,3,5,6-tetrahydroindole-5-semicarbazone-2-sulfonate sodium salt trihydrate It is a new generation of hemostatic drug developed by Mitsubishi Tanabe Pharmaceutical Co., Ltd. in Japan. It has the advantages of good hemostatic effect, rapid onset, long-lasting effect, and small side effects. It is mainly used in the urinary system, upper gastrointestinal tract, respiratory tract and gynecology. For obstetric hemorrhage, it has a more significant effect on the urinary system, and can also be used for the prevention and treatment of surgical bleeding.
卡络磺钠Sodium carbosulfonate
卡络磺钠已经上市的制剂类型主要有普通片剂、胶囊剂、散剂、颗粒剂、注射液和注射用粉针等,目前尚未见口腔崩解片上市,也未见相关研究报道。The types of preparations that have been marketed for sodium carbosulfonate mainly include ordinary tablets, capsules, powders, granules, injections and powder injections for injection, etc. At present, there are no orally disintegrating tablets on the market, and no relevant research reports have been seen.
发明内容 Contents of the invention
有鉴于此,本发明的目的之一在于提供一种卡络磺钠口腔崩解片,目的之二在于提供一种所述卡络磺钠口腔崩解片的制备方法。In view of this, one of the objectives of the present invention is to provide an orally disintegrating tablet of sodium carbene sulfonate, and the second objective is to provide a preparation method of the orally disintegrating tablet of sodium carbene sulfonate.
为达到上述目的,本发明采用如下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
1、卡络磺钠口腔崩解片,按质量百分比计由以下组分组成:卡络磺钠1%~15%、填充剂50%~90%、崩解剂5%~40%、粘合剂1%~8%、润滑剂0.1%~5%和矫味剂0.1%~5%。1. Orally disintegrating tablets of carbosulfonate sodium, composed of the following components by mass percentage: 1% to 15% of carbosulfonate sodium, 50% to 90% of filler, 5% to 40% of disintegrant, binder 1% to 8% of lubricants, 0.1% to 5% of lubricants and 0.1% to 5% of flavoring agents.
进一步,按质量百分比计由以下组分组成:卡络磺钠1%~10%、填充剂65%~85%、崩解剂5%~20%、粘合剂2%~6%、润滑剂0.1%~1%和矫味剂0.4%~1.5%;Further, it consists of the following components in terms of mass percentage: 1% to 10% of sodium carbosulfonate, 65% to 85% of filler, 5% to 20% of disintegrant, 2% to 6% of binder, lubricant 0.1%~1% and flavoring agent 0.4%~1.5%;
进一步,按质量百分比计由以下组分组成:卡络磺钠8%~9%、填充剂74%~80%、崩解剂6%~12%、粘合剂3%~5%、润滑剂0.4%~0.5%和矫味剂0.4%~1.0%;Further, it is composed of the following components in terms of mass percentage: 8% to 9% of sodium carbosulfonate, 74% to 80% of filler, 6% to 12% of disintegrant, 3% to 5% of binder, lubricant 0.4%~0.5% and flavoring agent 0.4%~1.0%;
进一步,所述填充剂为淀粉、预胶化淀粉、糊精、糖粉、乳糖、甘露醇、木糖醇、赤藓糖醇和微晶纤维素中的一种或多种;所述崩解剂为低取代羟丙基纤维素、交联羧甲基纤维素钠、交联羧甲基淀粉钠、交联聚维酮和泡腾崩解剂中的一种或多种,泡腾崩解剂由酒石酸、柠檬酸或富马酸与碳酸氢钠或碳酸钠组成;所述粘合剂为淀粉、甲基纤维素、乙基纤维素和羟丙甲基纤维素中的一种或多种;所述润滑剂为硬脂酸镁、滑石粉和微粉硅胶中的一种或多种;所述矫味剂为糖精钠、阿司帕坦、甜菊素和薄荷脑中的一种或多种;Further, the filler is one or more of starch, pregelatinized starch, dextrin, powdered sugar, lactose, mannitol, xylitol, erythritol and microcrystalline cellulose; the disintegrant It is one or more of low-substituted hydroxypropyl cellulose, croscarmellose sodium, croscarmellose sodium starch, crospovidone and effervescent disintegrant, effervescent disintegrant Composed of tartaric acid, citric acid or fumaric acid and sodium bicarbonate or sodium carbonate; the binder is one or more of starch, methylcellulose, ethylcellulose and hydroxypropylmethylcellulose; The lubricant is one or more of magnesium stearate, talcum powder and micronized silica gel; the flavoring agent is one or more of saccharin sodium, aspartame, stevia and menthol;
进一步,所述填充剂为淀粉、甘露醇和微晶纤维素中的一种或多种;所述崩解剂为交联聚维酮和/或泡腾崩解剂;所述粘合剂为羟丙甲基纤维素;所述润滑剂为硬脂酸镁;所述矫味剂为薄荷脑和/或阿司帕坦;Further, the filler is one or more of starch, mannitol and microcrystalline cellulose; the disintegrant is crospovidone and/or effervescent disintegrant; the binder is hydroxyl Propylmethylcellulose; The lubricant is magnesium stearate; The flavoring agent is Menthol and/or Aspartame;
进一步,所述填充剂为淀粉、甘露醇和微晶纤维素;所述崩解剂为交联聚维酮或者交联聚维酮和泡腾崩解剂,泡腾崩解剂由柠檬酸与碳酸氢钠组成;所述矫味剂为薄荷脑或者薄荷脑和阿司帕坦。Further, the filler is starch, mannitol and microcrystalline cellulose; the disintegrant is crospovidone or crospovidone and an effervescent disintegrant, and the effervescent disintegrant consists of citric acid and carbonic acid Composed of sodium hydrogen; the flavoring agent is menthol or menthol and aspartame.
2、所述卡络磺钠口腔崩解片的制备方法,采用湿法制粒压片法,包括以下步骤:2. The preparation method of the orally disintegrating tablet of sodium carbosulfonate adopts wet granulation and tabletting method, comprising the following steps:
a、粉碎:将填充剂、崩解剂、粘合剂、润滑剂和矫味剂分别粉碎成细度在100目以上的细粉;a. Pulverization: respectively pulverize fillers, disintegrants, binders, lubricants and flavoring agents into fine powders with a fineness above 100 mesh;
b、制粒:将卡络磺钠与部分填充剂混匀,粉碎,过80目筛;再与剩余填充剂、内加崩解剂、粘合剂、内加矫味剂混匀,过80目筛;再加入润湿剂制软材,20~40目筛制粒,60±5℃干燥,干颗粒过20~60目筛整粒;b. Granulation: mix sodium carbosulfonate with part of the filler, pulverize and pass through an 80-mesh sieve; Mesh sieve; add wetting agent to make soft material, granulate with 20-40 mesh sieve, dry at 60±5°C, pass through 20-60 mesh sieve for granulation;
c、压片:将步骤b整粒后的干颗粒与外加崩解剂、润滑剂、外加矫味剂混匀,压片,即得卡络磺钠口腔崩解片。c. Tablet compression: mix the dry granules sized in step b with additional disintegrants, lubricants, and additional flavoring agents, and then compress into tablets to obtain orally disintegrating tablets of sodium carbosulfonate.
进一步,所述步骤b中的润湿剂为体积分数为60%的乙醇水溶液;Further, the wetting agent in the step b is an aqueous ethanol solution with a volume fraction of 60%;
进一步,所述步骤b中采用24目筛制粒,干颗粒过24目筛整粒。Further, in the step b, a 24-mesh sieve is used for granulation, and the dry granules are passed through a 24-mesh sieve for granulation.
本发明的有益效果在于:本发明的卡络磺钠口腔崩解片表面光洁、美观,硬度适宜;不必用水送服,唾液即可使其在口腔内迅速崩解,服用方便,特别适合于老人、儿童、卧床或吞咽困难的患者,尤其是手术中或手术后出血而饮水不便的患者;口感清凉、甘甜、细腻,患者易于接受,服药依从性佳;崩解后的药物除部分随吞咽动作进入胃肠道外,有相当部分直接经口腔吸收,起效快,肝脏首过效应小,生物利用度高;进入胃肠道的药物为均匀分散的细微颗粒,在胃肠道中呈大面积分布,吸收点增多,对胃肠道的局部刺激减小;本发明采用湿法制粒压片法制备卡络磺钠口腔崩解片,生产工艺简单,制剂质量稳定易控,成本低廉,适合工业化大规模生产。The beneficial effect of the present invention is that: the orally disintegrating tablet of carbosulfonate of the present invention has a smooth and beautiful surface, and suitable hardness; it does not need to be taken with water, and saliva can make it disintegrate rapidly in the oral cavity, which is convenient to take, and is especially suitable for the elderly , children, patients who are bedridden or who have difficulty swallowing, especially those who suffer from bleeding during or after surgery and have difficulty drinking water; the taste is cool, sweet and delicate, easy for patients to accept, and the drug compliance is good; after disintegration, except for part of the drug, it follows the swallowing action After entering the gastrointestinal tract, a considerable part is directly absorbed through the oral cavity, with quick onset, small first-pass effect of the liver, and high bioavailability; the drug entering the gastrointestinal tract is uniformly dispersed fine particles, which are distributed in a large area in the gastrointestinal tract. The absorption point is increased, and the local irritation to the gastrointestinal tract is reduced; the present invention adopts the wet granulation and tabletting method to prepare orally disintegrating tablets of sodium carbosulfonate, the production process is simple, the preparation quality is stable and easy to control, and the cost is low, which is suitable for large-scale industrialization Production.
本发明为“重庆市兽药工程技术研究中心”研究项目。The invention is a research project of "Chongqing Veterinary Medicine Engineering Technology Research Center".
具体实施方式 Detailed ways
为了使本发明的目的、技术方案和优点更加清楚,下面将对本发明的优选实施例进行详细的描述。In order to make the object, technical solution and advantages of the present invention clearer, preferred embodiments of the present invention will be described in detail below.
本发明的卡络磺钠口腔崩解片,按质量百分比计由以下组分组成:The orally disintegrating tablet of sodium carbosulfonate of the present invention consists of the following components in terms of mass percentage:
卡络磺钠:1%~15%,优选1%~10%,更优选8%~9%;Sodium carbosulfonate: 1% to 15%, preferably 1% to 10%, more preferably 8% to 9%;
填充剂:50%~90%,优选65%~85%,更优选74%~80%;Filler: 50% to 90%, preferably 65% to 85%, more preferably 74% to 80%;
崩解剂:5%~40%,优选5%~20%,更优选6%~12%;Disintegrant: 5% to 40%, preferably 5% to 20%, more preferably 6% to 12%;
粘合剂:1%~8%,优选2%~6%,更优选3%~5%;Binder: 1% to 8%, preferably 2% to 6%, more preferably 3% to 5%;
润滑剂:0.1%~5%,优选0.1%~1%,更优选0.4%~0.5%;Lubricant: 0.1% to 5%, preferably 0.1% to 1%, more preferably 0.4% to 0.5%;
矫味剂:0.1%~5%,优选0.4%~1.5%,更优选0.4%~1.0%。Flavoring agent: 0.1% to 5%, preferably 0.4% to 1.5%, more preferably 0.4% to 1.0%.
所述填充剂选自淀粉、预胶化淀粉、糊精、糖粉、乳糖、甘露醇、木糖醇、赤藓糖醇和微晶纤维素中的一种或多种,优选淀粉、甘露醇和微晶纤维素中的一种或多种,更优选甘露醇、淀粉和微晶纤维素。淀粉性质非常稳定,价格便宜,吸湿性小,吸水性强且有一定膨胀性,适用于水不溶性或微溶性药物。甘露醇易溶于水,性质稳定,无吸湿性,甜度约相当于蔗糖的70%,因溶解时吸热,口腔中溶化时有清凉感。微晶纤维素不溶于水,具有良好的流动性和可压性,除作为填充剂外还兼有润滑和崩解作用,与溶胀性能强的低取代羟丙基纤维素、交联羧甲基纤维素钠、交联羧甲基淀粉钠、交联聚维酮联合应用时,可以提高片剂的孔隙率,增强毛细管作用,使片剂在少量水中即能快速崩解。The filler is selected from one or more of starch, pregelatinized starch, dextrin, powdered sugar, lactose, mannitol, xylitol, erythritol and microcrystalline cellulose, preferably starch, mannitol and microcrystalline cellulose. One or more of crystalline cellulose, more preferably mannitol, starch and microcrystalline cellulose. Starch is very stable in nature, cheap in price, low in hygroscopicity, strong in water absorption and has a certain swelling property, and is suitable for water-insoluble or slightly soluble drugs. Mannitol is easily soluble in water, stable in nature, non-hygroscopic, and its sweetness is about 70% that of sucrose. Because it absorbs heat when it dissolves, it has a cool feeling when it melts in the mouth. Microcrystalline cellulose is insoluble in water, has good fluidity and compressibility, in addition to being used as a filler, it also has lubricating and disintegrating functions, and low-substituted hydroxypropyl cellulose and cross-linked carboxymethyl cellulose with strong swelling properties When cellulose sodium, croscarmellose sodium, and crospovidone are used in combination, the porosity of the tablet can be increased, capillary action can be enhanced, and the tablet can be quickly disintegrated in a small amount of water.
所述崩解剂选自低取代羟丙基纤维素、交联羧甲基纤维素钠、交联羧甲基淀粉钠、交联聚维酮和泡腾崩解剂中的一种或多种,优选交联聚维酮和/或泡腾崩解剂,更优选交联聚维酮或者交联聚维酮和泡腾崩解剂。交联聚维酮具有很高的毛细管活性和水合能力,能迅速将水吸收到药片中,当内部压力即溶胀力超过药片的强度,药片即发生崩解,为高效片剂崩解剂。泡腾崩解剂由有机酸和弱碱组成,酸碱遇水反应生成二氧化碳气体从而使片剂快速崩解。在本发明中,所述泡腾崩解剂优选由酒石酸、柠檬酸或富马酸与碳酸氢钠或碳酸钠组成,更优选由柠檬酸与碳酸氢钠组成。The disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked sodium carboxymethyl starch, cross-linked povidone and effervescent disintegrants , preferably crospovidone and/or effervescent disintegrant, more preferably crospovidone or crospovidone and effervescent disintegrant. Crospovidone has high capillary activity and hydration ability, and can quickly absorb water into the tablet. When the internal pressure, that is, the swelling force exceeds the strength of the tablet, the tablet will disintegrate. It is a high-efficiency tablet disintegrating agent. The effervescent disintegrant is composed of organic acid and weak base. The acid and base react with water to generate carbon dioxide gas, which makes the tablet disintegrate rapidly. In the present invention, the effervescent disintegrant preferably consists of tartaric acid, citric acid or fumaric acid and sodium bicarbonate or sodium carbonate, more preferably citric acid and sodium bicarbonate.
所述粘合剂选自淀粉、甲基纤维素、乙基纤维素和羟丙甲基纤维素中的一种或多种,优选羟丙甲基纤维素。The binder is selected from one or more of starch, methylcellulose, ethylcellulose and hydroxypropylmethylcellulose, preferably hydroxypropylmethylcellulose.
所述润滑剂选自硬脂酸镁、滑石粉和微粉硅胶中的一种或多种,优选硬脂酸镁。The lubricant is selected from one or more of magnesium stearate, talcum powder and micronized silica gel, preferably magnesium stearate.
由于口腔崩解片在口腔内即崩解或溶解,故在制备口腔崩解片时应特别注意口感问题。本发明口腔崩解片中加入了矫味剂,所述矫味剂选自糖精钠、阿司帕坦、甜菊素和薄荷脑中的一种或多种,优选阿司帕坦和/或薄荷脑,更优选薄荷脑或者阿司帕坦和薄荷脑。Since orally disintegrating tablets disintegrate or dissolve in the oral cavity, special attention should be paid to the mouthfeel when preparing orally disintegrating tablets. A flavoring agent is added to the orally disintegrating tablet of the present invention, and the flavoring agent is selected from one or more of saccharin sodium, aspartame, stevia and menthol, preferably aspartame and/or peppermint Brain, more preferably menthol or aspartame and menthol.
本发明的卡络磺钠口腔崩解片采用湿法制粒压片法制备,包括以下步骤:The orally disintegrating tablet of sodium carbosulfonate of the present invention is prepared by a wet granulation tableting method, comprising the following steps:
a、粉碎:将填充剂、崩解剂、粘合剂、润滑剂和矫味剂分别粉碎成细度在100目以上的细粉;a. Pulverization: respectively pulverize fillers, disintegrants, binders, lubricants and flavoring agents into fine powders with a fineness above 100 mesh;
b、制粒:将卡络磺钠与部分填充剂混匀,粉碎,过80目筛;再与剩余填充剂、内加崩解剂、粘合剂、内加矫味剂混匀,过80目筛;再加入润湿剂制软材,20~40目筛制粒,60±5℃干燥,干颗粒过20~60目筛整粒;b. Granulation: mix sodium carbosulfonate with part of the filler, pulverize and pass through an 80-mesh sieve; Mesh sieve; add wetting agent to make soft material, granulate with 20-40 mesh sieve, dry at 60±5°C, pass through 20-60 mesh sieve for granulation;
c、压片:将步骤b整粒后的干颗粒与外加崩解剂、润滑剂、外加矫味剂混匀,压片,即得卡络磺钠口腔崩解片。c. Tablet compression: mix the dry granules sized in step b with additional disintegrants, lubricants, and additional flavoring agents, and then compress into tablets to obtain orally disintegrating tablets of sodium carbosulfonate.
在湿法制粒压片时应注意以下几点:(1)由于主药卡络磺钠的含水量约15%,单独粉碎时易粘连在机器上,且少量粘连成条块状,不易过筛;同时,填充剂淀粉的含水量也较高(一般为10%~15%),与主药混合粉碎较困难,不易过筛;因此,本发明中淀粉用前应在100~105℃先行干燥,使含水量在8%以下;同时,将卡络磺钠先与干燥淀粉混匀,粉碎,过筛,再与其它辅料混合。(2)崩解剂的常规加入方法有三种:①内加法:崩解剂与其它成分混合均匀后制粒,从而使崩解剂存在于颗粒内部,崩解虽较迟缓,但一经崩解便成细粒,有利于溶出;②外加法:崩解剂加在整粒后的干颗粒中,从而使崩解剂存在于颗粒之外和各颗粒之间,水份透入后,崩解迅速,但因颗粒内无崩解剂,不易崩解成细粒,溶出稍差;③内外加法:将崩解剂分成两份,一份按内加法加入,另一份按外加法加入。通过单因素试验研究发现,当崩解剂按内外加法加入时,更有利于口腔崩解片快速崩解。因此,本发明采用内外加法加入崩解剂。其中,泡腾崩解剂的加入方法为:将酸和碱的其中一种与其它成分混合均匀后制粒,另一种加在整粒后的干颗粒中,从而避免在湿法制粒时酸碱遇水发生反应。(3)由于矫味剂如薄荷脑等具有易挥发性,本发明选择在制粒前加入易挥发的矫味剂,尽量减少其挥发损失,剩余不易挥发的矫味剂则在制粒后加入,使所制片剂外层甘甜,在口感上更易被患者接受。The following points should be paid attention to during wet granulation and tabletting: (1) Since the water content of the main drug carbosulfonate is about 15%, it is easy to stick to the machine when it is crushed alone, and a small amount of sticks into strips, which is not easy to sieve Simultaneously, the water content of filler starch is also higher (generally 10%~15%), it is more difficult to mix and pulverize with the main ingredient, and it is not easy to sieve; therefore, starch should be dried in advance at 100~105°C before use in the present invention , so that the water content is below 8%; at the same time, the sodium carbosulfonate is firstly mixed with dry starch, crushed, sieved, and then mixed with other auxiliary materials. (2) There are three conventional methods of adding disintegrants: ①Internal addition: the disintegrant is mixed evenly with other ingredients and then granulated, so that the disintegrant exists inside the granules. Although the disintegration is slow, once disintegrated into fine particles, which is conducive to dissolution; ②External addition method: the disintegrating agent is added to the dry granules after granulation, so that the disintegrating agent exists outside the granules and between the granules. After the water penetrates, the disintegration is rapid. , but because there is no disintegrant in the granules, it is not easy to disintegrate into fine particles, and the dissolution is slightly poor; ③ Internal and external addition: Divide the disintegrating agent into two parts, one part is added by internal addition, and the other is added by external addition. Through the single factor test, it was found that when the disintegrating agent was added by internal and external addition, it was more conducive to the rapid disintegration of orally disintegrating tablets. Therefore, the present invention uses internal and external addition to add disintegrants. Among them, the method of adding the effervescent disintegrating agent is: mix one of the acid and the alkali with other ingredients and then granulate, and add the other to the dry granules after granulation, so as to avoid acid and alkali in wet granulation. Alkali reacts with water. (3) Due to the volatility of flavoring agents such as menthol, the present invention selects to add volatile flavoring agents before granulation to minimize its volatilization loss, and the remaining non-volatile flavoring agents are added after granulation , so that the outer layer of the prepared tablet is sweet, and it is easier to be accepted by patients in terms of mouthfeel.
研究发现,采用上述原辅料和方法制备的卡络磺钠口腔崩解片,表面光洁、美观,硬度适宜,在37±1℃水中30秒内即能完全崩解并通过30目筛,符合口腔崩解片的要求。The study found that the orally disintegrating tablets of carbosulfonium sodium prepared by using the above-mentioned raw materials and methods have a smooth, beautiful surface and appropriate hardness. They can completely disintegrate in 30 seconds in 37±1°C water and pass through a 30-mesh sieve, which meets the requirements of the oral cavity. Disintegrating Tablet Requirements.
实施例1Example 1
处方prescription
制法 将处方中除卡络磺钠外的所有组分分别粉碎成细度在100目以上的细粉;将淀粉在100~105℃干燥,使含水量在8%以下;将处方量的卡络磺钠和干燥淀粉混匀,粉碎,过80目筛;再与处方量的甘露醇、微晶纤维素、羟丙甲基纤维素和薄荷脑及1/2处方量的交联聚维酮混合,过80目筛;再加入体积分数为60%的乙醇水溶液适量制软材,24目筛制粒,60±5℃干燥,干颗粒过24目筛整粒;再在干颗粒中加入剩余交联聚维酮及处方量的硬脂酸镁,混匀,压片,共制成卡络磺钠口腔崩解片1000片,每片含卡络磺钠10mg。Preparation method: Grind all the components in the prescription except sodium carbosulfonate into fine powder with a fineness of more than 100 mesh; dry the starch at 100-105°C to keep the water content below 8%; Sodium sulfonate and dry starch are mixed, pulverized, and passed through an 80-mesh sieve; then mixed with prescription quantities of mannitol, microcrystalline cellulose, hydroxypropyl methylcellulose and menthol and 1/2 prescription quantities of crospovidone Mix and pass through a 80-mesh sieve; then add an appropriate amount of ethanol water solution with a volume fraction of 60% to make soft materials, granulate with a 24-mesh sieve, dry at 60±5°C, pass the dry granules through a 24-mesh sieve for granulation; then add the remaining Crospovidone and the prescribed amount of magnesium stearate were mixed evenly and tabletted to make 1000 orally disintegrating tablets of sodium carbosulfonate, each containing 10 mg of sodium carbosulfonate.
质量 所得口腔崩解片表面光洁、美观;硬度为22~27牛顿;在37±1℃水中24秒内完全崩解并通过30目筛;口感甘甜、清凉、细腻,无沙砾感。Quality The obtained orally disintegrating tablet has a smooth and beautiful surface; the hardness is 22-27 Newtons; it disintegrates completely in 24 seconds in water at 37±1°C and passes through a 30-mesh sieve; the taste is sweet, cool, delicate, and has no gritty feeling.
实施例2Example 2
处方prescription
制法 将处方中除卡络磺钠外的所有组分分别粉碎成细度在100目以上的细粉;将淀粉在100~105℃干燥,使含水量在8%以下;将处方量的卡络磺钠和干燥淀粉混匀,粉碎,过80目筛;再与处方量的甘露醇、微晶纤维素、柠檬酸、羟丙甲基纤维素和薄荷脑及1/2处方量的交联聚维酮混合,过80目筛;再加入体积分数为60%的乙醇水溶液适量制软材,24目筛制粒,60±5℃干燥,干颗粒过24目筛整粒;再在干颗粒中加入剩余交联聚维酮及处方量的碳酸氢钠和硬脂酸镁,混匀,压片,共制成卡络磺钠口腔崩解片1000片,每片含卡络磺钠10mg。Preparation method: Grind all the components in the prescription except sodium carbosulfonate into fine powder with a fineness of more than 100 mesh; dry the starch at 100-105°C to keep the water content below 8%; Sodium sulfonate and dry starch are mixed, pulverized, and passed through an 80-mesh sieve; then cross-linked with mannitol, microcrystalline cellulose, citric acid, hydroxypropyl methylcellulose and menthol and 1/2 of the prescription amount Mix povidone and pass through a 80-mesh sieve; then add an appropriate amount of ethanol aqueous solution with a volume fraction of 60% to make soft materials, granulate with a 24-mesh sieve, dry at 60±5°C, and pass the dry granules through a 24-mesh sieve for granulation; Add the sodium bicarbonate and magnesium stearate of remaining crospovidone and prescription quantity in, mix, tabletting, make 1000 tablets of orally disintegrating sodium carbosulfonate altogether, each contains sodium carbosulfonate 10mg.
质量 所得口腔崩解片表面光洁、美观;硬度为21~28牛顿;在37±1℃水中23秒内完全崩解并通过30目筛;口感清凉、甘甜、细腻,无沙砾感。Quality The obtained orally disintegrating tablet has a smooth and beautiful surface; the hardness is 21-28 Newtons; it disintegrates completely in 23 seconds in water at 37±1°C and passes through a 30-mesh sieve; the taste is cool, sweet, delicate, and free of grit.
实施例3Example 3
处方prescription
制法 将处方中除卡络磺钠外的所有组分分别粉碎成细度在100目以上的细粉;将淀粉在100~105℃干燥,使含水量在8%以下;将处方量的卡络磺钠和干燥淀粉混匀、粉碎,过80目筛;再与处方量的甘露醇、微晶纤维素、羟丙甲基纤维素和薄荷脑及1/2处方量的交联聚维酮混合,过80目筛;再加入体积分数为60%的乙醇水溶液适量制软材,24目筛制粒,60±5℃干燥,干颗粒过24目筛整粒;再在干颗粒中加入剩余交联聚维酮及处方量的硬脂酸镁和阿司帕坦,混匀,压片,共制成卡络磺钠口腔崩解片1000片,每片含卡络磺钠10mg。Preparation method: Grind all the components in the prescription except sodium carbosulfonate into fine powder with a fineness of more than 100 mesh; dry the starch at 100-105°C to keep the water content below 8%; Sodium sulfonate and dry starch are mixed, pulverized, and passed through an 80-mesh sieve; then mixed with prescription quantities of mannitol, microcrystalline cellulose, hydroxypropyl methylcellulose and menthol and 1/2 prescription quantities of crospovidone Mix and pass through a 80-mesh sieve; then add an appropriate amount of ethanol water solution with a volume fraction of 60% to make soft materials, granulate with a 24-mesh sieve, dry at 60±5°C, pass the dry granules through a 24-mesh sieve for granulation; then add the remaining Cross-linked povidone, magnesium stearate and aspartame in the prescribed amount were mixed evenly, and tabletted to make 1000 orally disintegrating tablets of sodium carbosulfonate, each containing 10 mg of sodium carbosulfonate.
质量 所得口腔崩解片表面光洁、美观;硬度为22~27牛顿;在37±1℃水中25秒内完全崩解并通过30目筛;口感清凉、甘甜、细腻,无沙砾感。Quality The obtained orally disintegrating tablet has a smooth and beautiful surface; the hardness is 22-27 Newtons; it disintegrates completely in 25 seconds in 37±1°C water and passes through a 30-mesh sieve; the taste is cool, sweet, fine and smooth, without gritty feeling.
实施例4Example 4
处方prescription
制法 将处方中除卡络磺钠外的所有组分分别粉碎成细度在100目以上的细粉;将淀粉在100~105℃干燥,使含水量在8%以下;将处方量的卡络磺钠和干燥淀粉混匀、粉碎,过80目筛;再与处方量的甘露醇、微晶纤维素、柠檬酸、羟丙甲基纤维素和薄荷脑及1/2处方量的交联聚维酮混合,过80目筛;再加入体积分数为60%的乙醇水溶液适量制软材,24目筛制粒,60±5℃干燥,干颗粒过24目筛整粒;再在干颗粒中加入剩余交联聚维酮及处方量的碳酸氢钠、硬脂酸镁和阿司帕坦,混匀,压片,共制成卡络磺钠口腔崩解片1000片,每片含卡络磺钠10mg。Preparation method: Grind all the components in the prescription except sodium carbosulfonate into fine powder with a fineness of more than 100 mesh; dry the starch at 100-105°C to keep the water content below 8%; Sodium sulfonate and dry starch are mixed, pulverized, and passed through an 80-mesh sieve; then cross-linked with mannitol, microcrystalline cellulose, citric acid, hydroxypropylmethylcellulose and menthol and 1/2 of the prescription amount Mix povidone and pass through a 80-mesh sieve; then add an appropriate amount of ethanol aqueous solution with a volume fraction of 60% to make soft materials, granulate with a 24-mesh sieve, dry at 60±5°C, and pass the dry granules through a 24-mesh sieve for granulation; Add the remaining crospovidone and the prescribed amount of sodium bicarbonate, magnesium stearate and aspartame, mix well, and press into tablets to make 1000 orally disintegrating tablets of sodium carbosulfonate, each containing calorie Sodium Sulfate 10mg.
质量 所得口腔崩解片表面光洁、美观;硬度为17~27牛顿;在37±1℃水中28秒内完全崩解并通过30目筛;口感清凉、甘甜、细腻,无沙砾感。Quality The obtained orally disintegrating tablet has a smooth and beautiful surface; the hardness is 17-27 Newtons; it disintegrates completely in 28 seconds in water at 37±1°C and passes through a 30-mesh sieve; the taste is cool, sweet, delicate, and has no gritty feeling.
实施例5Example 5
处方prescription
制法 将处方中除卡络磺钠外的所有组分分别粉碎成细度在100目以上的细粉;将淀粉在100~105℃干燥,使含水量在8%以下;将处方量的卡络磺钠和干燥淀粉混匀、粉碎,过80目筛;再与处方量的甘露醇、微晶纤维素、柠檬酸、羟丙甲基纤维素和薄荷脑及1/2处方量的交联聚维酮混合,过80目筛;再加入体积分数为60%的乙醇水溶液适量制软材,24目筛制粒,60±5℃干燥,干颗粒过24目筛整粒;再在干颗粒中加入剩余交联聚维酮及处方量的碳酸氢钠、硬脂酸镁和阿司帕坦,混匀,压片,共制成卡络磺钠口腔崩解片1000片,每片含卡络磺钠10mg。Preparation method: Grind all the components in the prescription except sodium carbosulfonate into fine powder with a fineness of more than 100 mesh; dry the starch at 100-105°C to keep the water content below 8%; Sodium sulfonate and dry starch are mixed, pulverized, and passed through an 80-mesh sieve; then cross-linked with mannitol, microcrystalline cellulose, citric acid, hydroxypropylmethylcellulose and menthol and 1/2 of the prescription amount Mix povidone and pass through a 80-mesh sieve; then add an appropriate amount of ethanol aqueous solution with a volume fraction of 60% to make soft materials, granulate with a 24-mesh sieve, dry at 60±5°C, and pass the dry granules through a 24-mesh sieve for granulation; Add the remaining crospovidone and the prescribed amount of sodium bicarbonate, magnesium stearate and aspartame, mix well, and press into tablets to make 1000 orally disintegrating tablets of sodium carbosulfonate, each containing calorie Sodium Sulfate 10mg.
质量 所得口腔崩解片表面光洁、美观;硬度为23~28牛顿;在37±1℃水中30秒内完全崩解并通过30目筛;口感清凉、甘甜、细腻,无沙砾感。Quality The obtained orally disintegrating tablet has a smooth and beautiful surface; the hardness is 23-28 Newtons; it disintegrates completely in 30 seconds in water at 37±1°C and passes through a 30-mesh sieve; the taste is cool, sweet, delicate, and free of grit.
实施例6Example 6
处方prescription
制法 将处方中除卡络磺钠外的所有组分分别粉碎成细度在100目以上的细粉;将淀粉在100~105℃干燥,使含水量在8%以下;将处方量的卡络磺钠和干燥淀粉混匀、粉碎,过80目筛;再与处方量的甘露醇、微晶纤维素、柠檬酸、羟丙甲基纤维素和薄荷脑及1/2处方量的交联聚维酮混合,过80目筛;再加入体积分数为60%的乙醇水溶液适量制软材,24目筛制粒,60±5℃干燥,干颗粒过24目筛整粒;再在干颗粒中加入剩余交联聚维酮及处方量的碳酸氢钠、硬脂酸镁和阿司帕坦,混匀,压片,共制成卡络磺钠口腔崩解片1000片,每片含卡络磺钠10mg。Preparation method: Grind all the components in the prescription except sodium carbosulfonate into fine powder with a fineness of more than 100 mesh; dry the starch at 100-105°C to keep the water content below 8%; Sodium sulfonate and dry starch are mixed, pulverized, and passed through an 80-mesh sieve; then cross-linked with mannitol, microcrystalline cellulose, citric acid, hydroxypropylmethylcellulose and menthol and 1/2 of the prescription amount Mix povidone and pass through a 80-mesh sieve; then add an appropriate amount of ethanol aqueous solution with a volume fraction of 60% to make soft materials, granulate with a 24-mesh sieve, dry at 60±5°C, and pass the dry granules through a 24-mesh sieve for granulation; Add the remaining crospovidone and the prescribed amount of sodium bicarbonate, magnesium stearate and aspartame, mix well, and press into tablets to make 1000 orally disintegrating tablets of sodium carbosulfonate, each containing calorie Sodium Sulfate 10mg.
质量 所得口腔崩解片表面光洁、美观;硬度为25~28牛顿;在37±1℃水中28秒内完全崩解并通过30目筛;口感清凉、甘甜、细腻,无沙砾感。Quality The obtained orally disintegrating tablet has a smooth and beautiful surface; the hardness is 25-28 Newtons; it disintegrates completely in 28 seconds in 37±1°C water and passes through a 30-mesh sieve; the taste is cool, sweet, delicate, and free of grit.
本发明的卡络磺钠口腔崩解片与市售的卡络磺钠普通片的溶出度比较Dissolution comparison of the orally disintegrating tablets of sodium carbosulfonate of the present invention and commercially available sodium carbosulfonate ordinary tablets
方法:分别取本发明各实施例制备的卡络磺钠口腔崩解片和市售的卡络磺钠普通片,以水900mL为溶出介质,转速为每分钟50转,照中国药典2005年版二部附录XC第二法操作,分别在1、5、10、15、20、25、30、45分钟时,取溶液5mL,滤过,取续滤液作为供试品溶液,在波长363nm处测定吸收度,按C10H11N4O5SNa的吸收系数(E1%1 cm)为862计算溶出度。结果见下表。由表可见,与市售的卡络磺钠普通片相比,本发明的卡络磺钠口腔崩解片具有崩解快、溶出快、溶出度高等特点。Method: get respectively the orally disintegrating tablets of sodium carbosulfonate prepared by each embodiment of the present invention and commercially available ordinary tablets of sodium carbosulfonate, take water 900mL as the dissolution medium, and the rotating speed is 50 revolutions per minute, according to Chinese Pharmacopoeia 2005 edition two Part Appendix XC second method operation, respectively at 1, 5, 10, 15, 20, 25, 30, 45 minutes, take 5mL of the solution, filter, take the subsequent filtrate as the test solution, and measure the absorption at a wavelength of 363nm According to the absorption coefficient (E 1% 1 cm ) of C 10 H 11 N 4 O 5 SNa is 862 to calculate the dissolution rate. The results are shown in the table below. As can be seen from the table, compared with commercially available sodium carbosulfonate ordinary tablets, the orally disintegrating tablet of sodium carbosulfonate of the present invention has the characteristics of fast disintegration, fast dissolution and high dissolution rate.
表卡络磺钠口腔崩解片和卡络磺钠普通片的溶出度比较Comparison of Dissolution Rates between Orally Disintegrating Tablets of Epicarbosulfonate Sodium and Common Tablets of Epicarbosulfonate Sodium
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管通过参照本发明的优选实施例已经对本发明进行了描述,但本领域的普通技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离所附权利要求书所限定的本发明的精神和范围。Finally, it is noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described with reference to the preferred embodiments of the present invention, those skilled in the art should understand that it can be described in the form Various changes may be made in matter and details thereof without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101290751A CN101797235B (en) | 2010-03-19 | 2010-03-19 | Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101290751A CN101797235B (en) | 2010-03-19 | 2010-03-19 | Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101797235A CN101797235A (en) | 2010-08-11 |
CN101797235B true CN101797235B (en) | 2012-05-09 |
Family
ID=42593178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101290751A Expired - Fee Related CN101797235B (en) | 2010-03-19 | 2010-03-19 | Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101797235B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107970217A (en) * | 2016-10-25 | 2018-05-01 | 浙江京新药业股份有限公司 | Cariliprazine oral disnitegration tablet and preparation method thereof |
CN115813870B (en) * | 2022-12-21 | 2024-05-10 | 江苏吴中医药集团有限公司 | Carbazochrome sodium sulfonate tablet and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1985808A (en) * | 2006-12-20 | 2007-06-27 | 山东省医药工业研究所 | Carbazochrome sodium sulfonate slow-released tablet and its preparing method |
CN101554377A (en) * | 2008-04-09 | 2009-10-14 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate |
-
2010
- 2010-03-19 CN CN2010101290751A patent/CN101797235B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1985808A (en) * | 2006-12-20 | 2007-06-27 | 山东省医药工业研究所 | Carbazochrome sodium sulfonate slow-released tablet and its preparing method |
CN101554377A (en) * | 2008-04-09 | 2009-10-14 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate |
Non-Patent Citations (1)
Title |
---|
贾伟、高文远,主编.口腔崩解片.《药物控释新剂型》.化学工业出版社、现代生物技术与医药科技出版中心,2005,(第1版),8-15. * |
Also Published As
Publication number | Publication date |
---|---|
CN101797235A (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4989733B2 (en) | Orally disintegrating tablets | |
PT1145711E (en) | Flash-melt oral dosage formulation | |
WO2005037254A1 (en) | Tablet quickly disintegrating in oral cavity | |
WO2005037319A1 (en) | Composition for tablet rapidly disintegrable in mouth | |
JP2009114113A (en) | Intraorally disintegrable tablet and method for producing the same | |
JPH0948726A (en) | Rapidly disintegrating preparation in mouth cavity and its production | |
KR20130030306A (en) | Pharmaceutical compositions | |
WO2005055989A1 (en) | Drug-containing grains and solid preparation containing the grains | |
JP7336388B2 (en) | Tablet and its manufacturing method | |
JP2004175796A (en) | Intraoral disintegrating preparation for treating dysuria | |
JP2001163770A (en) | Intraorally rapid disintegration tablet and method for producing the same | |
CN102488681B (en) | Ibuprofen diphenhydramine orally disintegrating tablet and preparation method thereof | |
JP2002255796A (en) | Rapidly disintegrating tablet in oral cavity and method for producing the same | |
CN102440973B (en) | Diphenhydramine citrate orally disintegrating tablet and preparation method thereof | |
ES2694644T3 (en) | New composition of alfentanil for the treatment of acute pain | |
CN102178658B (en) | Lappaconitine hydrobromide orally disintegrating tablets and preparation method thereof | |
JPH11199517A (en) | Intraoral fast disintegrable tablet | |
JP2013533881A (en) | Pharmaceutical composition containing vanoxerin | |
CN101797236B (en) | Rivastigmine orally disintegration tablet and preparation method thereof | |
JP2010270040A (en) | Orally disintegrating tablets | |
JP3228335B2 (en) | Orally disintegrating composition and method for producing the same | |
CN101797235B (en) | Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof | |
CN101690720A (en) | Carteolol orally disintegrating tablets and preparation method thereof | |
CN101797237A (en) | Betahistine mesilate orally disintegrating tablet and preparation method thereof | |
CN102309460B (en) | Pyridostigmine bromide odor masking orally disintegrating tablets and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 Termination date: 20180319 |